A Study on the Effectiveness of Decitabine Combined with a Half-Dose Priming Regimen in the Treatment of Elderly Patients with Acute Myeloid Leukemia

Abstract

Objective: To investigate the clinical effects of combining decitabine with a half-dose priming regimen in the treatment of elderly patients with acute myeloid leukemia. Methods: This study was conducted in Shaanxi Provincial People’s Hospital from January 2019 to January 2022. Sixty patients were recruited as the research subjects. The patients received different treatments and were randomly divided into two groups, with 30 cases in each group, one of which was treated with conventional priming regimen (control group), and the other was treated with decitabine combined with a half-dose priming regimen (study group). The two groups were compared and analyzed in terms of the effectiveness of treatment. Results: The rate of symptom relief in the study group was 96.67%, which was significantly higher than that in the control group (76.67%) (p < 0.05). Before treatment, there was no significant difference in the quality-of-life scores between the two groups, with p > 0.05. The patients in the study group had significantly longer disease-free survival and overall survival than those in the control group, with p < 0.05. The effectiveness of treatment in the study group was also better. Conclusion: The use of decitabine in combination with a half-dose priming regimen for the treatment of elderly patients with acute myeloid leukemia is effective in improving patients’ quality of life, relieving symptoms, and prolonging their survival.